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Introduction
Ceftriaxone, a parenteral third-generation cephalosporin, is used to treat serious bacterial 
infections and sexually transmitted diseases.1 Inappropriate ceftriaxone use contributes to 
resistance to this important antibiotic and threatens patient safety due to antibiotic-associated 
adverse events and Clostridioides difficile infections.2 Previous studies of inappropriate 
antibiotic prescribing in outpatient acute respiratory infections (ARIs) have focused on oral, 
rather than parenteral, antibiotics.3,4 Our objective was to describe ceftriaxone use in adult 
outpatient ARI visits.
Methods
We identified adult (18-64 years) visits to urgent care, retail health, and physician office 
settings that occurred from January 1, 2014 to December 31, 2014 in the IBM® 
MarketScan® Commercial Database (IBM® Watson Health™, Ann Arbor, MI). This 
database contains insurance claims from a convenience sample of several million individuals 
under age 65 with private, employer-sponsored insurance from over 260 employers.5 We 
identified unique visits by date, enrollee number, and place of service. We excluded records 
without enrollee numbers or ICD-9-CM diagnosis codes. We excluded enrollees without 
coverage in MarketScan for ≥30 days prior to the outpatient visit. To exclude higher-acuity 
patients potentially warranting empiric ceftriaxone therapy, we excluded visits with previous 
(≤30 days) hospital discharges or same-day admissions.
We aggregated all claims for each visit to identify all diagnoses and ceftriaxone injections. 
We used a previously described tiered-diagnosis system3 modified for ceftriaxone 
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indications (Supplementary Table) to assign a single diagnosis to each visit. We identified 
ceftriaxone injections using Healthcare Common Procedure Coding System code J0696. We 
excluded visits with concurrent diagnoses for conditions where ceftriaxone could be 
permissible (sexually transmitted infections and related diagnoses [e.g. cervicitis], 
pneumonia, urinary tract infection, sickle cell disease, and acute suppurative otitis media). 
We defined ceftriaxone-inappropriate ARIs as sinusitis, pharyngitis, bronchitis, viral upper 
respiratory infection, and influenza. We calculated per-visit ceftriaxone rates by dividing the 
number of outpatient visits with ceftriaxone by total outpatient visits for ceftriaxone-
inappropriate ARIs. We estimated confidence intervals using a binomial distribution. The 
National Center for Emerging and Zoonotic Infectious Diseases human subjects advisor 
determined this study to be non-human subjects research not requiring Institutional Review 
Board review. Analyses were conducted using DataProbe 5.0 (IBM® Watson Health™) and 
SAS version 9.4 (SAS Institute, Cary, NC). Statistical tests were conducted at α=0.05.
Results
In 2014, there were 9,653,688 adult outpatient visits for ceftriaxone-inappropriate ARIs. 
Ceftriaxone injections were given in 3.5% (95% CI 3.5%-3.5%) of these (Table). The per-
visit ceftriaxone rate in the South was 6.9% (95% CI 6.9%-7.0%), the highest of all regions, 
and the South accounted for 84.3% of all ceftriaxone injections. In the South, the highest 
ceftriaxone rate occurred in physician offices (7.3%, 95% CI 7.3%-7.3%).
Discussion
Despite being an inappropriate treatment, ceftriaxone injections occurred in 3.5% of adult 
outpatient ARI visits in this study. Over 80% of inappropriate ceftriaxone injections 
occurred in the South. In our study, we excluded visits with ceftriaxone-permissible 
diagnoses and individuals potentially warranting empiric ceftriaxone therapy; therefore, 
regional differences are likely due to differences in provider behavior rather than clinical 
factors. Previous studies of oral antibiotics demonstrate higher rates of unnecessary3,6 and 
broad-spectrum7,8 prescribing in the South. Although underlying health may be worse in the 
South,9 there may also be a tendency among clinicians in this region to prescribe/administer 
medications, even when not clinically appropriate. Further research on regional differences 
in clinician behavior is needed.
Our study has limitations. These data are a convenience sample of privately-insured 
individuals <65 and may not be generalizable to other populations; we were not able to 
evaluate the representativeness of this sample. Additionally, as these were claims data, we 
made assumptions to assign a single diagnosis to a visit and were unable to evaluate the dose 
of ceftriaxone given. A strength of this study is the ability to examine parenteral antibiotic 
use in multiple outpatient settings in a large sample.
Although ceftriaxone was used in only 3.5% of adult visits for ceftriaxone-inappropriate 
ARIs, this translates to 338,394 likely unnecessary exposures in this sample alone. 
Inappropriate ceftriaxone use in outpatient ARI management puts patients at risk for adverse 
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events, C. difficile, and antibiotic-resistant infections. Stewardship of this important 
antibiotic is urgently needed, especially in the South.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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